ExploreWatchlistsPricing
  1. JP-listed companies
  2. SanBio Company Limited
  3. Financials
  4. Operating income

SanBio Company Limited (4592)

Market cap
¥159.8B
P/E ratio
-28.4x
SanBio develops cell therapy drugs to help patients recover brain and nervous system functions lost due to injury or diseases like Parkinson's and Alzheimer's.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndOperating income (Million JPY)YoY (%)
Jan 31, 2026-3,795+7.93%
Jan 31, 2025-3,516-22.55%
Jan 31, 2024-4,540-42.53%
Jan 31, 2023-7,899+19.31%
Jan 31, 2022-6,621+14.12%
Jan 31, 2021-5,802+5.75%
Jan 31, 2020-5,486+46.93%
Jan 31, 2019-3,734-14.72%
Jan 31, 2018-4,378+126.60%
Jan 31, 2017-1,932+71.72%
Jan 31, 2016-1,125-150.04%
Jan 31, 20152,249

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat